Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 20/20 | 0.64 |
| ▸ | PDE4A | P27815 | 9/20 | 0.64 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | VEGFA | P15692 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | PDE5A | O76074 | 1/20 | 0.64 |
| ▸ | TNF | P01375 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | PDE1A | P54750 | 1/20 | 0.64 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL185270 | 1.00 | PDE4B (0.64) | PDE4BPDE4APDE4CPDE4DCYP3A4 | |
| SCHEMBL3632907 | 1.00 | PDE4B (0.64) | PDE4BPDE4APDE4CPDE4DCYP3A4 | |
| SCHEMBL185271 | 1.00 | PDE4B (0.64) | PDE4BPDE4APDE4CPDE4DCYP3A4 | |
| SCHEMBL525130 | 1.00 | PDE4B (0.64) | PDE4BPDE4APDE4CPDE4DCYP3A4 | |
| SCHEMBL31396386 | 1.00 | PDE4B (0.64) | PDE4BPDE4APDE4CPDE4DCYP3A4 | |
| SCHEMBL31396436 | 1.00 | PDE4B (0.64) | PDE4BPDE4APDE4CPDE4DCYP3A4 | |
| SCHEMBL185272 | 1.00 | PDE4B (0.64) | PDE4BPDE4APDE4CPDE4DCYP3A4 | |
| SCHEMBL185568 | 1.00 | PDE4B (0.64) | PDE4BPDE4APDE4CPDE4DCYP3A4 | |
| SCHEMBL5190103 | 0.92 | PDE4B (0.64) | PDE4BPDE4APDE4CPDE4DCYP3A4 | |
| SCHEMBL4373922 | 0.78 | PDE4B (0.71) | PDE4BPDE4APDE4CPDE4DCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 565 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200237735-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A P13 DELTA OR DUAL P13 DELTA-GAMMA KINASE INHIBITOR | RHIZEN PHARMACEUTICALS AG (CH) | 2020-07-30 | — | — | US | claimed |
| US-10058539-B2 | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor | RHIZEN PHARMACEUTICALS SA (CH) | 2018-08-28 | — | — | US | claimed |
| US-20170319558-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | RHIZEN PHARMACEUTICALS AG (CH) | 2017-11-09 | — | — | US | claimed |
| US-20150272936-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | RHIZEN PHARMACEUTICALS AG (CH) | 2015-10-01 | — | — | US | claimed |
| EP-2916868-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | Rhizen Pharmaceuticals S.A. (CH) | 2015-09-16 | — | — | EP | claimed |
| EP-1305329-B2 | 6.ALPHA.,9.ALPHA.-DIFLUORO-17.ALPHA.-(2-FURANYLCARBOXYL)OXY-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT | GLAXO GROUP LTD (GB) | 2015-03-18 | — | — | EP | claimed |
| WO-2014072937-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | RHIZEN PHARMACEUTICALS SA (CH) | 2014-05-15 | — | — | WO | claimed |
| EP-2598145-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF RESPIRATORY AND INFLAMMATORY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2013-06-05 | — | — | EP | claimed |
| US-20120196875-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | US | claimed |
| WO-2012013567-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF RESPIRATORY AND INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | WO | claimed |
| US-20070037781-A1 | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-15 | — | — | US | claimed |
| US-20060286041-A1 | MRP IV INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-21 | — | — | US | claimed |
| US-20060270667-A1 | NOVEL MEDICAMENT COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-30 | — | — | US | claimed |
| WO-2006015775-A2 | EGFR KINASE INHIBITOR COMBINATIONS FOR TREATING RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | WO | claimed |
| US-20060035893-A1 | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | US | claimed |
| EP-1616567-A1 | Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2006-01-18 | — | — | EP | claimed |
| WO-2005102349-A1 | PHARMACEUTICAL COMBINATIONS CONTAINING BENZOXAZINE FOR TREATING RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | claimed |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2005-10-27 | — | — | US | claimed |
| US-20050043343-A1 | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-24 | — | — | US | claimed |
| US-20050026886-A1 | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026886-A1 | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor | PDE12, PDE3A, PDE3B | PDE4B 5/4885PDE4A 6/4885PDE4C 11/4885 |
| US-20060270667-A1 | NOVEL MEDICAMENT COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | ADRB3, CHRM3, ADRB2 | PDE4B 10/4885PDE4A 20/4885PDE4C 35/4885 |
| US-20120196875-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND INFLAMMATORY DISEASES | PDE4B, PDE4A, PDE12 | PDE4B 1/4885PDE4A 2/4885PDE4C 6/4885 |
| US-20070037781-A1 | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient | ADRB2, ADRA2A, ADRB1 | PDE4B 285/4885PDE4A 335/4885PDE4C 616/4885 |
| US-20060286041-A1 | MRP IV INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | ABCB1, ABCC4, ABCC1 | PDE4B 651/4885PDE4A 687/4885PDE4C 1508/4885 |
| US-20170319558-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | PIK3CD, PIK3R4, PIK3CG | PDE4B 6/4885PDE4A 5/4885PDE4C 10/4885 |
| US-20200237735-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A P13 DELTA OR DUAL P13 DELTA-GAMMA KINASE INHIBITOR | PDE4A, PDE12, PDE4B | PDE4B 3/4885PDE4A 1/4885PDE4C 8/4885 |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | MRGPRX2, MRGPRX1, MTNR1B | PDE4B 354/4885PDE4A 626/4885PDE4C 923/4885 |
| US-20050043343-A1 | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor | PDE3A, PDE4B, PDE12 | PDE4B 2/4885PDE4A 6/4885PDE4C 19/4885 |
| US-20060035893-A1 | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders | BDKRB2, EDNRB, GRK5 | PDE4B 21/4885PDE4A 32/4885PDE4C 89/4885 |
| US-20150272936-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | PIK3CD, PIK3R4, PIK3CG | PDE4B 6/4885PDE4A 5/4885PDE4C 10/4885 |
| US-10058539-B2 | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor | PIK3CD, PIK3R4, PIK3CG | PDE4B 6/4885PDE4A 5/4885PDE4C 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.